Mr. Fleming, an executive biotech professional with more than 26 years of experience in the biopharmaceutical industry, joined Coherus in 2014. Mr. Fleming has held senior leadership or executive management team roles at several companies including Elan Corporation, Nuvelo, Inc., Genentech, GlaxoSmithKline, SmithKline Beecham and inVentiv Health. At Elan Corporation plc., Mr. Fleming was Senior Vice President of Commercial and Tysabri Brand with responsibility for leading the commercial organization and Elan’s efforts in the global commercial Tysabri collaboration with Biogen Idec. Prior to that role, he spent several years as a management consultant at inVentiv Health Consulting (Campbell Alliance), heading up their Western US Biotech Corporate Development Practice. Before joining inVentiv Health, Mr. Fleming was Vice President, Commercial Operations at Nuvelo, Inc. as well as Head of Hematology Marketing at Genentech where he was responsible for overseeing the U.S. Rituxan hematology/oncology commercial effort. At GlaxoSmithKline, he was the worldwide commercial strategy lead for Zofran & Supportive Care. Mr. Fleming has also held executive positions at GlaxoSmithKline Canada and its predecessor companies, including Vice President, HIV Oncology Vaccines Business Unit and Vice President, Healthcare Policy and Market Access. In this role, in addition to leading a lobbyist unit, he was responsible for developing commercial reimbursement and health economics strategy for the organization. Mr. Fleming earned a Microbiology Specialist Degree (BSc) at Victoria College, University of Toronto, and an MBA at the Rotman School of Business, University of Toronto.

He has been instrumental in the launch, commercial and business development of numerous products in various therapeutic areas, including: HIV, infectious diseases, diabetes, CNS conditions, multiple sclerosis, cardiovascular and oncology.